Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance

Abbott LaboratoriesTrade
SP Funds S&P 500 Sharia Industry Exclusions ETFTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Abbott Laboratories trades at $109.69 (market cap $187.95B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59. The key difference: Abbott Laboratories pays a 2.32% dividend while SP Funds S&P 500 Sharia Industry Exclusions ETF pays none, and SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.

ABTSPUS
Market Cap
$187.95B
Sector
HealthBroad Market / Factor
52-Week High
$136.62$59.51
52-Week Low
$82.57$46.28
Enterprise Value
$214.96B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.

Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.

SP Funds S&P 500 Sharia Industry Exclusions ETF

SPUS trades at $59.16, up 0.82% today, with a bullish technical signal from moving averages but bearish oscillators. Recent dividends of $0.03 per share were declared for mid-2026. The stock shows strong institutional interest and competitive dividend strategies amid market concentration in tech stocks.

Outlook remains positive due to dividend stability and technical support, but overbought RSI signals caution. Risks include market volatility and reliance on dividend performance. Analysts monitor earnings growth as a key catalyst for sustained upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About SP Funds S&P 500 Sharia Industry Exclusions ETF

SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.

Read more on SPUS